The Vaccine World Summit India 2013 conference has honored Novavax, Cadila Pharmaceuticals Biologicals (CPLB) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) collaboration for having the 'most promising vaccine for emerging diseases in India'.
In 2012, the three organizations have partnered to combine Novavax's vaccine technology, ICGEB's malaria vaccine research expertise and CPLB manufacturing capability.
India's Department of Biotechnology Vaccine Grand Challenge Program is funding the project while the Malaria Vaccine Development Program is managing the project.
Novavax president and CEO Stanley Erck said, "Malaria remains a major public health problem in many parts of the tropical world and we are committed to identifying a safe and effective vaccine that can prevent its spread and devastating effects."
